OncoSec granted rights to patent portfolio for IL-12 DNA with checkpoint inhibitors
OncoSec announced the Company has been granted exclusive worldwide rights to Gaeta Therapeutics' broad portfolio of patents and applications covering the combination use of IL-12 DNA and various checkpoint inhibitor therapies, including anti-CTLA-4 and anti-PD--1 compounds, in key global markets.
May 21, 2019